

# Medicinal Chemistry 2

## Sulfonamides (Sulfa drugs)

Dr. Mamdouh Fawzy Ahmed  
Faculty of Pharmacy  
Sohag University

# Sulfonamides (Sulfa drugs)

## Antibiotics

### Definition


- ❑ 1942, Waksman “an antibiotic is a substance produced by microorganisms which has the capacity of inhibiting the growth & destroying other microorganisms”.
- ❑ Later “ any substance produced by a living organism that is capable of inhibiting the growth or survival of one or more species of microorganisms in low concs.
- ❑ medicinal chemists to modify the natural antibiotics to prepare new synthetic analogs so we now have *semisynthetic* & *synthetic* derivatives in the definition.

### Classification of Antibiotics

<b><i>β-Lactam</i></b>	Penicillins & Cephalosporins
<b><i>Non- β-Lactam</i></b>	Aminoglycoside: Streptomycin & Kanamycin
	Tetracyclines
	Macrolides: Erythromycin & Oleandomycin
	Polypeptide: Polymixin
	Polyene: Amphotericin
	Miscellaneous : Chloramphenicol

# Sulfonamides (Sulfa drugs)


## Mechanisms of action of antibacterial drugs [5]



# Sulfonamides (Sulfa drugs)

## **Bacterial Cell Wall**

Human cells have **no cell wall**, but bacterial cells need a cell wall which composed of Peptidoglycan & Proteins. since they have a **hypotonic environment** in which the cell functions. If no cell wall, bacterial cells would rupture leading to cell death..




- ❖ These differences are the key for treatment of bacterial diseases by use of antibiotics.
- ❖ Without such differences it would be difficult to target and kill bacterial cells once they get into human body.

# Sulfonamides (Sulfa drugs)

## Discovery:

- ❖ In 1932: Domagk studied the antimicrobial effect of Prontosil Dye "brilliant red Dye" → it was found to be active  $\neq$  Streptococcal infection in mice [*in vivo*] but inactive on bacterial culture [*in vitro*].




Prontosil Dye (prodrug)

# Sulfonamides (Sulfa drugs)

## Discovery:

- ❖ In 1935: Trefouel discovered the conversion of inactive prontosil dye -in vivo- into active Sulfanilamide "Lead cpd or Prototype". This finding was confirmed by isolating free sulfonamide from blood & urine of patients treated with Prontosil.






- ❖ Prontosil is inactive in vitro but in vivo → sulfanilamide (active form) by reductive cleavage
- ❖ This led to discovery of the first synthetic antibacterial agent

# Sulfonamides (Sulfa drugs)

## Chemistry of sulfonamide

Chemistry of sulfonamide: they are classified as

[1] <u>Aniline-substituted sulfonamide</u>	[2] <u>Prodrugs giving active sulfonamide</u>	[3] <u>Non-aniline sulfonamides</u>
 <p><u>Sulfanilamides</u></p>	 <p><u>Sulfasalazine</u></p>	 <p><u>Mafenide acetate</u></p>

# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:


- Sulphanilamides are active BACTERIOSTATIC [ so, eradication of m. o. is by normal immunity of body ].
- Many bacteria are impermeable to folic acid, so they rely on their ability to synthesize folate from PABA “P-AminoBenzoic Acid” , Pteridine & Glutamate ≠ MAMMALS who can't synthesize folic acid, so obtained from diet & so not affected by sulfonamides [selective chemotherapy].
- Because of their structural similarity to PABA ,Sulphonamides act as competitive reversible inhibitor with this substrate for the enzyme DIHYDROPTEROATE SYNTHETASE ,thus ↓ synthesis of folic acid → ↓ thymidine, purine synthesis → ↓ synthesis of DNA → ↓ multiplication & growth of m.o.



# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:





### Biosynthesis of folate co-enzymes:



# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

By using sulfonamides



# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

This mechanism is supported by:

- ❖ 1. PABA added to culture media antagonizes effect of sulfonamides.
- ❖ 2. Man can't form folic acid  $\therefore$  so his cells are immune to sulfonamides.
- ❖ 3. M.O. which can utilize preformed folic acid are less sulfonamides susceptible.

# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

Resistance of m.o. to sulfonamide drugs by:


- ❖ 1. The bacterial cell wall becomes more permeable to folic acid.
- ❖ 2. The m.o. learn to utilize preformed folic acid.
- ❖ 3. The organism develop alternate pathway for synthesis of folic acid.
- ❖ 4. increase PAPA synthesis by m.o. to overcome inhibition of dihydropteroate synthetase.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA → more active.


Sulfa drugs



# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA → more active.




### Change in A

- ❑ Free  $\text{NH}_2$  is essential for activity.
- ❑ Removal of  $\text{NH}_2 \rightarrow$  inactive compounds.
- ❑ Alkylation of  $\text{NH}_2 \rightarrow$  inactive compounds.
- ❑ Shifting  $\text{NH}_2$  gp to *m*- or *o*-position ► inactive compounds.
- ❑ Substitution with  $\text{NO}_2$ ,  $\text{NHOH}$ , azo or acetylation ► prodrugs which upon reduction or hydrolysis in vivo ► free  $\text{NH}_2$  (e.g. intestinal sulfa) still retain its activity.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA → more active.




### Change in B

1. Phenyl group is essential: replacement with naphthalene, anthracene, pyridine or by another heterocyclic rings or saturation to cyclohexyl → inactive compounds.
2. Substitution on benzene ring by halogen or any other group ► loss of activity.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA → more active.



### Change in C


1. SO<sub>2</sub> must be **directly** attached to benzene ring.
2. R should be **electron withdrawing group** ▶ ↑ acidity ▶ ↓ pKa ▶ ↑ ionization ▶ ↑ activity
3. N is best to be N-acyl "**prodrug**" this will help in;
  - Mask the **bitter taste** (can be used orally as syrup).
  - Hydrolyzed **in vivo** to give **free active** compound.



# Sulfonamides (Sulfa drugs)

## Physicochemical properties of sulfa drugs

[1] They are weak organic acids: due to  $\text{SO}_2\text{NH}_2$  group [by loss of proton & stabilization of  $-ve$  charge by resonance], & this determine  $\text{pK}_a$  of the drug.





N.B: acidity increases by attachment of e-withdrawing group to N4

# Sulfonamides (Sulfa drugs)

## Physicochemical properties of sulfa drugs

2- Amphoteric characters: [with acidic & basic characters] React as acid & base




The deprotonated form (in -OH medium) is more stable due to resonance stabilization

So, in when we make urine alkaline, we increase solubility [increase ionized form]

# Sulfonamides (Sulfa drugs)

## Synthesis of sulfonamides




## 2- Solubility of sulfa drugs

All sulfonamides are **insoluble in water** except the sodium salts, on the other hand all sulfonamides are **soluble in alkali** except sulfaguanidine, while all sulfonamides are soluble in acids.

# Sulfonamides (Sulfa drugs)

## Metabolism:

- By N4-acetylation: sulfonamides excreted as it's + N4-acetate + glucuronide [both are inactive]
- N4-acetate is less water soluble than parent drug, which lead to increase tendency of crystalluria



[less water soluble than parent drug so, make crystalluria]

**Crystallurea:** precipitation of sulfonamide (has low water solubility) which may cause kidney damage

# Sulfonamides (Sulfa drugs)

## Crystallurea & PKa

•According to the following equation:

$$pka_{\text{drug}} = pH_{\text{urine}} + \log \frac{\text{Unionized form of the drug}}{\text{Ionized form of the drug}}$$

- ❖ If pH of urine = pka of drug  $\Rightarrow$  ionized/unionized = 1
- ❖ If pka of drug > pH of urine  $\Rightarrow$  unionized/ionized > 1  $\Rightarrow$  ↓ solubility
- ❖ If pka of drug < pH of urine  $\Rightarrow$  unionized/ionized < 1  $\Rightarrow$  ↑ solubility

# Sulfonamides (Sulfa drugs)

## Crystallurea & PKa

•According to the following equation:





$$pka_{\text{drug}} = pH_{\text{urine}} + \log \frac{\text{Unionized form of the drug}}{\text{Ionized form of the drug}}$$

❖ pH of urine is about 6 & pka of sulfanilamide is 10.4 → so present in urine in unionized form → ↓↓ solubility → crystalluria & bleeding.

# Sulfonamides (Sulfa drugs)

## Crystallurea & PKa

To solve problem of crystalluria:

- ❖ 1. Drinking large amount of water  $\rightarrow$   urine flow by  rate of glomerular filtration.
- ❖ 2. Combination therapy [ triple therapy ] : using mixed sulphonamides [ 3 sulpha drugs: Sulfadiazine + Sulfamerazine + Sulfamethazine]  $\rightarrow$  only 1/3 of the amount of each drug is used giving the same bacterial action but each one is present in amount less than its solubility product  $\rightarrow$  no precipitation.
- ❖ 3.  pH of urine by alkalization [ using  $\text{NaHCO}_3$  ]
- ❖ 4.  pka of drug by N1-substitution with electron-withdrawing group [as heterocycle or acyl group]

# Sulfonamides (Sulfa drugs)

## Crystalluria & PKa

### Question

if pka of sulfisoxazole is 5, determine its risk of crystalluria.

$$5 = 7 + \log \frac{\text{Unionized}}{\text{Ionized}}$$

$$\log \frac{\text{Unionized}}{\text{Ionized}} = -2 \quad \Rightarrow \quad \frac{\text{Unionized}}{\text{Ionized}} = \frac{1}{100}$$

❖ So, it's present mainly in ionized form → more soluble → less risk of crystalluria.




# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

[1] Methods depends on aromatic amino group [ N4 ] :  
**Diazotization**

1. Dissolve in dil.HCl & titrate  $\neq$  M/10 NaNO<sub>2</sub>  $\Rightarrow$  diazonium salt.
2. E.p. is determined by ;
  - KI/starch as external indicator.
  - Potentiometrically.
  - Colorimetrically  $\Rightarrow$  by coupling diazonium salt with  $\beta$ -naphthol in NaOH  $\Rightarrow$  colored compound.




# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

### [2] Methods depend on acidity of sulphonamides [ -SO<sub>2</sub>NH<sub>2</sub> ]

[a] Non-aqueous titration	[b] Argentometric method [ Back titration ]
<ul style="list-style-type: none"><li>As they are weak acids → dissolve in pyridine or DMF [basic solvent] &amp; titrate ≠ NaOCH<sub>3</sub>.</li><li>E.p. determined using thymol blue as indicator.</li></ul>	<ul style="list-style-type: none"><li>Add known xss of std. AgNO<sub>3</sub> in NaOH → insol. Ag Salt + equivalent amount of HNO<sub>3</sub>.</li><li>Ag salt is filtered out.</li><li>Either back titration of xss unreacted AgNO<sub>3</sub> in Filtrate ≠ NH<sub>4</sub>SCN &amp; ferric alum indicator [Volhard]</li></ul>




# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

### [3] Bromometric method


1. Add known xss of standard  $\text{Br}_2$  solution in  $\text{HCl} \rightarrow$  bromination of sulphonamides.
2. xss  $\text{Br}_2$  determined by adding  $\text{KI} \rightarrow \text{I}_2 \rightarrow$  titrated  $\neq$  std  $\text{Na}_2\text{S}_2\text{O}_3$

e.g. Sulfadiazine



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides



### [i] Systemic Sulfoanmides

Used in treatment of systemic infections.

Classified according to rate of excretion [ $t_{1/2}$ ] into:


SHORT ACTING	MEDIUM ACTING	LONG ACTING
Taken every 6 hrs	Taken every 8-12 hrs	Taken every 24 hrs
$t_{1/2} < 10$ hrs	$t_{1/2} = 10-24$ hrs	With slow excretion rate

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides




### [i] Systemic Sulfoanmides



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [1] N1-Acyl Derivatives



N-[(4-aminophenyl) sulfonyl] acetamide  
OR [N<sup>1</sup>-acetyl sulphanilamide]

- ❑ Water soluble, its solution with pka 5.4 [acidic]  $\rightarrow$   $\downarrow\downarrow$  risk of crystalluria.
- ❑ Its Na salt is less alkaline than Na salts of other sulfonamides  $\rightarrow$  non-irritant to mucous membrane  $\Rightarrow$  used as eye drops till 30 % concentration.
- ❑ Can be used for urinary tract infection [why?]  $\rightarrow$  it's highly soluble with  $t_{1/2} = 7$  hrs [rapid excretion]

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative

[ii] Pyridazine Derivative


[iii] Isoxazole Derivative

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative (short acting)




**Sulfamethazine**

$t_{1/2} = 7$  hrs /  $pK_a = 7.2$

More water soluble > sulfadiazine & sulfamerazine in acidic urine [pH=5.5], but lower activity in vitro & in vivo.

Used in combination sulfa [Tri-sulfapyrimidine therapy]

N<sup>1</sup>( 4,6-dimethyl- 2- pyrimidinyl ) Sulphanilamide



**Sulfisomidine**

$t_{1/2} = 7.5$  hrs

The most water soluble of pyrimidine derivatives → ↓↓ tendency of crystalluria.

N<sup>1</sup>( 2,6-dimethyl- 4- pyrimidinyl ) Sulphanilamide



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative (moderate or intermediate acting)

$t_{1/2} = 17$  hrs /  $pK_a = 6.3$

Broad spectrum, the drug of choice in UTI.


$\text{NaHCO}_3$  is co-given [why ?]

#### Uses:

Na salt as 5 % solution (IV) : In Meningitis [penetrate into CSF].


Ag salt : topically in burns.

Sulfadiazine



N<sup>1</sup>(2- pyrimidinyl ) Sulphanilamide

Sulfamerazine



N<sup>1</sup>(4-methyl-2- pyrimidinyl ) Sulphanilamide

$t_{1/2} = 27$  hrs

Similar properties to sulfadiazine, but:

With more water solubility.

More absorbable.

Less excretion rate.


Higher blood level can be obtained with a similar dose.

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides


### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative (long acting)  
Sulfameter



N<sup>1</sup>(5-methoxy -2- pyrimidinyl)  
Sulphanilamide

Sulfadimethoxine



N<sup>1</sup>(2,6-dimethoxy-4- pyrimidinyl)  
Sulphanilamide

Long duration of action due to **presence of OCH<sub>3</sub>** :

↑ plasma protein binding.

Drug-Plasma protein complex is too large to pass through kidney glomerular membrane  
→ ↓ excretion → long duration.

This binding also ↓ free form of drug → ↓ metabolism → longer duration.

As a result of ↓ excretion → may cause **hypersensitivity** upon accumulation.

$t_{1/2}$  of Sulfameter is 37-48 hrs & for Sulfadimethoxine is 40 hrs.

sulfameter with **bitter taste** → not used in liquid preparations → **make N<sup>1</sup>-acetyl derivative [Prodrug]**.

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative

#### Synthesis of Pyrimidine derivatives:

#### Synthesis of Sulfadiazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative

##### Synthesis of Pyrimidine derivatives:

##### Synthesis of Sulfamerazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative

#### Synthesis of Pyrimidine derivatives:

#### Synthesis of Sulfamethazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [ii] Pyridazine Derivative

#### [ii] Pyridazine Derivative


##### Sulfachloropyridazine



N<sup>1</sup>(6-chloro-3-pyridazinyl) Sulphanilamide

- $t_{1/2} = 8$  hrs  $\rightarrow$  short acting.
- Used in treatment of urinary tract infections.


##### Sulfamethoxypyridazine



N<sup>1</sup>(6-methoxy-3-pyridazinyl) Sulphanilamide

- $t_{1/2} = 37$  hrs  $\rightarrow$  long acting [why?] , due to presence of methoxy group.
- With bitter taste.

##### Sulfamethoxypyridazine acetyl



N<sup>1</sup>-acetyl-N<sup>1</sup>(6-methoxy-3-pyridazinyl) Sulphanilamide

- **PRODRUG** for sulfamethoxypyridazine  $\rightarrow$   $\downarrow$  bitter taste  $\rightarrow$  used for pediatrics.
- Inactive in vitro  $\rightarrow$  activated by deacetylation in intestine.

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[iii] Isoxazole Derivative

[iii] Isoxazole Derivative


#### Sulfamethoxazole



N<sup>1</sup>(5-methyl-3-isoxazolyl) Sulphanilamide

- $t_{1/2} = 11$  hrs  $\rightarrow$  short acting.
- Not rapidly absorbed as sulfisoxazole  $\rightarrow$  its peak blood level is only about 50 %.


#### Sulfaisoxazole



N<sup>1</sup>(3,4-dimethyl-5-isoxazolyl) Sulphanilamide

- $t_{1/2} = 6$  hrs  $\rightarrow$  short acting.
- Rapidly absorbed.
- Highly water soluble  $\rightarrow$  no need for using alkalinizing agent with it.
- With bitter taste.

#### Sulfaisoxazole acetyl



N<sup>1</sup>-acetyl-N<sup>1</sup>(3,4-dimethyl-5-isoxazolyl) Sulphanilamide

- **PRODRUG** for sulfaisoxazole  $\rightarrow$   $\downarrow$  bitter taste  $\rightarrow$  used for liquid oral preparations.
- Inactive in vitro  $\rightarrow$  activated by deacetylation in intestine.
- Less soluble than sulfisoxazole.

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] topical Sulfoanmides

Sulfacetamide :-

#### [1] N<sup>1</sup>-Acyl Derivatives

##### Sulfacetamide



N-[(4-aminophenyl) sulfonyl ]  
acetamide  
OR [N<sup>1</sup>-acetyl sulphanilamide]

- Water soluble, its solution with pka 5.4 [acidic] → ↓↓ risk of crystalluria.
- Its Na salt is **less alkaline** than Na salts of other sulfonamides → **non-irritant to mucous membrane** → used as **eye drops** till 30 % concentration.
- Can be used for **urinary tract infection** [why?] → it's highly soluble with  $t_{1/2} = 7$  hrs [rapid excretion]



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] topical Sulfoanmides

Sulfadiazine Silver [Silvadene]

Mafenide acetate

#### Sulfadiazine Silver [Silvadene]




- Applied in water-miscible cream [**Dermazine®**] → active topically ≠ *Pseudomonas* species → used in **burn therapy** [that *Pseudomonas* is responsible for failure of therapy]
- Slightly soluble, **Not** penetrate cell wall but act on external cell structures.
- Prepared by mixing equimolar amount of **AgNO<sub>3</sub>** & **Na sulfadiazine** [both dissolved in water].

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] topical Sulfoanmides

#### Mafenide acetate



- **NOT TRUE SULFONAMIDE COMPOUND**  
**[NOT TYPICAL SULFONAMIDE]**
- Not inhibited by PABA [its M.O.A. involve different **unknown mechanism** than true sulfonamides].
- Not affected by pH.
- Effective  $\neq$  *Clostridium welchii* in topical use for infected wounds.
- Not effective orally.
- Used alone or with antibiotics in ttt of slow healing infected wounds.
- If used in large quantities  $\rightarrow$  **metabolic acidosis**. So, a series of new organic salts was prepared.
- The **acetate derivative** in ointment base is the most efficient.


# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] topical Sulfoanmides

Mafenide metabolism

#### METABOLISM:



Both Mafenide & its metabolite [P-carboxy benzene sulfonamide] cause INHIBITION OF CARBONIC ANHYDRASE ENZYME  $\rightarrow$  METABOLIC ACIDOSIS.

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides


### [3] non-absorbable Sulfoanmides

[i] Topical Sulfonamides : Sulfadiazine Ag & Mafenide acetate.

#### [ii] Intestinal Sulfonamides

- They are **PRODRUGS** designed to be poorly absorbed, in large intestine → cleavaged → free sulfonamide "active".
- Used in treatment of intestinal infections, ulcerative colitis & reduction of bowel flora.

#### sulfaguanidine



N<sup>1</sup>-amidino sulfanilamide

- Guanidine is a basic moiety that cause:
  1. ↓ absorption.
  2. ↓ lipid solubility.
- Poorly absorbed [with additional basic group] → not absorbed from GIT → high local concentration.

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides

#### N<sup>4</sup>-substituted Sulfonamides


[Acylation with Dicarboxylic acids "Succinic & Phthalic acids]

##### Succinyl sulphathiazole




2-(N<sup>4</sup>-succinyl sulfanilamide) thiazole

##### Phthalyl sulphathiazole



2-(N<sup>4</sup>-**phthalyl** sulfanilamide) thiazole

##### Phthalyl sulphacetamide



N<sup>4</sup>-**acetyl**-N<sup>4</sup>-phthalyl sulfanilamide

They have additional acidic group → poorly absorbed from GIT.

They are **PRODRUGS** → activated in vivo by slow hydrolysis giving ↑ local concentration.


With little use now

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides


#### sulfasalazine



5-[4-(2-pyridyl sulfamoyl) phenyl azo]  
salicylic acid

**ONLY SULFAPYRIDINE DERIVATIVE.**  
**ONLY USED IN ULCERATIVE COLITIS.**

- Water insoluble, broken in body giving: **m-amino saicyclic acid** [anti-inflammatory] + **Sulfapyridine** [anti-bacterial]  
→ so, it acts as carrier for 5-amino salicylic acid → **USED IN ULCERATIVE COLITIS** it




# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides

#### Synthesis:



It occurs by electrophilic substitution reaction at P-position of salicylic acid [why?]



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### Adverse effects of sulfonamides therapy:

Gastrointestinal distress.

Hemolytic anemia.

Hepatitis.

Stevens-Johnson Syndrome [sever skin eruption].

**Crystalluria.**




# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

Combination of sulfonamides with  
Dihydrofolate Reductase Inhibitor

### Trimethoprim



It's **potent anti-bacterial** by inhibition of DHFR enzyme → → stop bacterial growth.  
**Selective in action** → 100.000 times more active ≠ bacterial DHFR relative to mammalian DHFR. [used for **UTI**]


Combined with **Sulfamethoxazole** as both have the same pharmacokinetic properties [t<sub>1/2</sub> = hrs like that of sulfamethoxazole] → excreted at about the same time. [important condition for combination between two drugs]

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### Combination of sulfonamides with Dihydrofolate Reductase Inhibitor

M.O.A of combination:




**Remember** 😊 : ↓ THFA synthesis → ↓ purine & pyrimidine bases synthesis → ↓ DNA synthesis → stop growth of bacteria.

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

Combination of sulfonamides with  
Dihydrofolate Reductase Inhibitor

### Trimethoprim



Trimethoprim combined with Sulfamethoxazole [Sutrim<sup>®</sup>][Septazole<sup>®</sup>][Septrin<sup>®</sup>]

#### Advantages of this combination:

1. Synergism due to sequential blockage.
2. Avoid development of resistance [if use sulfamethoxazole alone].
3. Broader spectrum of activity.
4. Bactericidal instead of Bacteriostatic.

# Sulfonamides (Sulfa drugs)

## Important notes

### Sulfonamides

- Prototype is Sulfanilamide [from prontosil prodrug].
- Bacteriostatic NOT bactericidal
- Act by competitive inhibition of dihydropteroate synthetase enzyme → inhibit folic acid synthesis → inhibit DNA synthesis.
- Structurally similar to PABA → as structure more similar to PABA, it becomes more active.
- Crystalluria → sulpha & acetyl metabolites are sparingly soluble in water.
- ↑ pH or urine or ↓ pka of drug → ↓ risk of crystalluria.
- ↓ pka → ↑ solubility → ↓ risk of crystalluria → UTI.
- Assay: depend on acidity [non-aqueous/argentometry], basicity [diazotization] / bromometry.
- Sulfacetamide Na salt is less alkaline than Na salts of other sulfa drugs → due to higher acidity → eye drops.
- ↑ methyl groups on pyrimidine → ↑ solubility.
- Methoxy group → bind to plasma proteins → long duration.
- To overcome bitter taste of sulfa drugs → acetyl prodrug on N<sup>1</sup>.
- Ag sulfadiazine [act on external cell structure] & mafenide acetate [NOT true sulfa] → used topically for burns.
- Additional basic or acidic moiety → intestinal sulfa.
- Sulfasalazine → only pyridine derivative → only used in ulcerative colitis.
- Best combination → Sulfamethoxazole [DHPS inhibitor] + Trimethoprim [DHFR inhibitor]

# Sulfonamides (Sulfa drugs)

## Sample questions

### Questions

#### ① [a] Complete the following :

1. Compound A has generic name: -----

Its chemical name is -----

It's used for ----- while its silver salt is used for -----

It can be assayed by -----

-----

How can you synthesize compound A:

2. Sulpha triple therapy has the advantages of -----

3. Sulfonamides are metabolized mainly by -----

4. Sulfonamides are made more soluble in urine by -----, -----, -----or -----



5. Duration of action of ----- [sulfa drug] is long due to -----

6. Sulfacetamide is used for ----- due to -----

7. Sutrim is a combination of ----- & ----- . Its advantages are -----, -

-----, ----- & -----

8. In the bromometric assay for determination of the compound B, it consumes ----- molecules of Bromine.




# Sulfonamides (Sulfa drugs)

## Sample questions

9. Compound C is more water soluble than sulfadiazine.

It has the advantage -----

-----



10. N<sup>4</sup>-acylaiton with dicarboxylic acid yields a sulfonamide used in -----

11. The following mechanisms may be seen in species resistant to sulfonamide therapy:

1. -----
2. -----
3. -----

12. The mode of action of sulfonamides involves -----

13. Sulphonamides are assayed by :

[a] -----




[b] -----

[c] -----

14. The ----- salt of sulfadiazine is used topically while ----- salt is used I.V.

15. The basic intestinal sulfonamide is ----- while the acidic intestinal sulfonamides are -----,  
-----, -----

7. To design a long acting sulfonamide, the condensation step in preparation of sulpha can be done with:



# Sulfonamides (Sulfa drugs)

## Sample questions







**[b] In determination of activity of some sulfa drugs, the following data were reported:**

Drug	A) Sulfanilamide	B) Sulfacetamide	C) Sulfamethazine
pka	10.4	7.2	5.4

- Determine which one with the lowest risk of crystalluria [illustrate your answer with calculation].
- C is preferred over A for urinary tract infection.
- A is the best one used as eye drops.
- Starting from A, how can you synthesize B & C.

T F  
T F

**[c]**




Compound	Active / Inactive	The reason
1		
2		
3		
4		
5		
6		

# Sulfonamides (Sulfa drugs)

## Sample questions

[a] Modify the drawn structure into two derivatives acting locally :



Drug A : -----  
used as -----  
because -----  
-----  
Chemical name :-----  
-----

Drug B : -----  
used for -----  
because -----  
-----  
Chemical name :-----  
-----


[b] Give a direct assays of sulfadiazine & another back titration.

[c] What's the effect of the following modifications on 4-aminobenzene sulfonamide?

- [a] Replacing amino group by methyl amino.
- [b] Replacing amino group by amino methyl.
- [c] Addition of amidino group to  $\text{N}^1$ .
- [d] Action of acetyltransferase.
- [e] Increase pH of urine from 5 to 7.
- [f] Substitution of acidic center with 4,6-dimethoxy-2-pyrimidinyl.

[d] A new product with the drawn structure was designed, it's expected to be active in: [Rationalize your answer]

- [a] Intestinal infections & ulcerative colitis.
- [b] Intestinal infections.
- [c] Ulcerative colitis.
- [d] Non of the above.





# NSAIDS

The end

THANK YOU  
FOR YOUR  
ATTENTION